SCHEMBL2569729

SCHEMBL2569729

CN(C(C)(C)C)S(=O)(=O)c1ccc(Cl)nc1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.61
MAPT P10636 1/20 0.59
ALDH1A1 P00352 9/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
POLB P06746 1/20 0.43
CYP2D6 P10635 1/20 0.41
EDNRA P25101 1/20 0.39
GAA P10253 2/20 0.39
EGFR P00533 2/20 0.39
PKM P14618 1/20 0.39
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL671244 0.82 SMN1; SMN2 (0.69) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL12077838 0.77 MAPT (0.73) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL6701096 0.77 SMN1; SMN2 (0.61) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL26931067 0.75 ALDH1A1 (0.61) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL30693037 0.75 SMN1; SMN2 (0.51) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL17645850 0.75 MAPT (1.00) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL6697256 0.74 SMN1; SMN2 (0.58) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL2571556 0.74 ALDH1A1 (0.56) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL29977958 0.72 SMN1; SMN2 (0.59) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL4804914 0.72 SMN1; SMN2 (0.59) SMN1; SMN2MAPTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359329-B2 Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof SANOFI (FR) 2016-06-07 US disclosed
US-20160137627-A9 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2016-05-19 US disclosed
US-20140194470-A1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-07-10 US disclosed
US-8697731-B2 Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof SANOFI (FR) 2014-04-15 US disclosed
US-20110301148-A1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-12-08 US disclosed
EP-2382215-A1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-11-02 EP disclosed
WO-2010076525-A1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160137627-A9 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF NR3C2, NR3C1, NR5A2 SMN1; SMN2 1634/4885MAPT 4313/4885ALDH1A1 2557/4885
US-20140194470-A1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF NR3C2, NR3C1, NR5A2 SMN1; SMN2 1634/4885MAPT 4313/4885ALDH1A1 2557/4885
US-20110301148-A1 DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF NR3C2, NR3C1, NR5A2 SMN1; SMN2 1634/4885MAPT 4313/4885ALDH1A1 2557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.